Intercept raises $30M in series C
13:23 EDT 9 Aug 2012 | BioCentury
Intercept Pharmaceuticals Inc. (New York, N.Y.) raised $30 million in a series C round led by OrbiMed Advisors. Existing investor Genextra S.p.A. (Milan, Italy) participated. Intercept's obeticholic acid is in the international Phase III POISE trial..
Original Article: Intercept raises $30M in series C
More From BioPortfolio on "Intercept raises $30M in series C"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
